Klaus Mantwill

Mr. Klaus Mantwill

Urology Research, Technical University of Munich
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Klaus MantwillKlaus Mantwill
Klaus Mantwill
FKFlorian Gerhard Klein
Florian Gerhard Klein
DWDongbiao Wang
Dongbiao Wang
SVSruthi Hindupur Vasantamadhava
Sruthi Hindupur Vasantamadhava
MEMaximilian Ehrenfeld
Maximilian Ehrenfeld
Roman NawrothRoman Nawroth
Roman Nawroth
Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the management of various cancers. Different concepts of modification within the adenovirus vector have been identified that define the mode of action against and the interaction with the tumour. Adenoviral vectors allow for genetic manipulations that restrict tumour specificity and also the expression of specific transgenes in order to support the anti-tumour effect. Additionally, replication of the virus and reinfection of neighbouring tumour cells amplify the therapeutic effect. Another important aspect in oncolytic adenovirus therapy is the virus induced cell death which is a process that activates the immune system against the tumour. This review describes which elements in adenovirus vectors have been identified for modification not only to utilize oncolytic adenovirus vectors into conditionally replicating adenoviruses (CRAds) that allow replication specifically in tumour cells but also to confer specific characteristics to these viruses. These advances in development resulted in clinical trials that are summarized based on the conceptual design.

Verified
Journal Article
Open access
PDF file
AHAnna Carolina Hogger
Anna Carolina Hogger
THTing Hong
Ting Hong
Klaus MantwillKlaus Mantwill
Klaus Mantwill
NGNadine Gaisa
Nadine Gaisa
JGJürgen E. Gschwend
Jürgen E. Gschwend
Roman NawrothRoman Nawroth
Roman Nawroth
Treatment of metastatic breast cancer with CDK4/6 inhibitors in combination with hormone ablation is the current first-line standard of care for this indication, and the therapeutic activity of these inhibitors has been demonstrated in various tumor entities. However, the efficacy of CDK4/6 inhibitor monotherapy is limited and requires combination with suitable additional inhibitors. Delineating the molecular pathways underlying treatment response may provide a rationale for personalized combination therapies that target deregulated pathways upstream of the core signature of response. We applied a comprehensive cross-omics approach to identify a conserved molecular response to CDK4/6 inhibition. Integration of transcriptomic, proteomic, and functional genomic data across multiple cancer models enabled us to refine a previously proposed multi-step model of response to the CDK4/6 inhibitor palbociclib. Initiation of cell-cycle arrest and inhibition of DNA replication is followed by activation of signaling events that suppress mitotic transcriptional programs. The identified panel of highly conserved candidate biomarkers warrants future experimental and clinical validation.